2024-11-20

Join us for the PolTREG Q3 2024 financial results webinar!

2024-11-14

PolTREG received a new patent from China for anti-gen specific Tregs cellular therapy

2024-10-24

PolTREG launches Phase 2 cell therapy trial in children with presymptomatic diabetes

2024-09-26

PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases

2024-09-16

China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis

2024-09-11

Join us for the PolTREG H1 2024 financial results webinar!

2024-09-09

PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence

2024-07-24

The European Medicines Agency has granted PolTREG preliminary approval to launch a new Phase 2 clinical trial in presymptomatic Type-1 Diabetes.